Suzetrigine for Cancer-Related Bone Pain: A Three-Patient Case Series

Cancer-related bone pain remains a clinical challenge, particularly in patients with metastatic disease who have failed conventional pharmacologic therapies. Suzetrigine, a selective NaV1.8 sodium channel inhibitor, is a novel non-opioid analgesic with potential utility in nociceptive and neuropathic pain states. However, its role in advanced cancer-related pain remains unclear. We present a three-patient case series evaluating suzetrigine in patients with metastatic cancer involving the spine. All patients had extensive prior treatment histories, including opioid therapy, and demonstrated no meaningful improvement in pain following a three-week trial of suzetrigine. Treatment was discontinued due to lack of efficacy, and in one case, cost was also a contributing factor. No adverse effects were reported. These findings highlight potential limitations of suzetrigine in advanced cancer-related bone pain, particularly in opioid-tolerant patients.